Financial Data and Key Metrics Changes - Total oncology revenue for 2025 was $286 million, including $71 million from R&D-related upfront and milestone revenues [5] - Net income recorded was $457 million, primarily due to a one-time gain from the SHPL divestment of $160 million; core operations remained profitable excluding this gain [5] - R&D expenses decreased to $148 million in 2025, lower than in 2024 due to many late-stage trials nearing completion [6] Business Line Data and Key Metrics Changes - Ex-China sales of FRUZAQLA grew by 26% year-over-year, reaching $366 million in in-market sales [3] - China sales rebounded in the second half of 2025, achieving 21% growth compared to the first half [3] - ORPATHYS and Surufatinib accounted for 11% of total EMARC sales, facing challenges due to competition [10] Market Data and Key Metrics Changes - In the U.S., sales faced headwinds from Medicare Part D redesign, impacting growth [9] - China sales under the brand name ELUNATE experienced a decline of 13% in the first half but rebounded with 33% growth in the second half [9] - The ITP market in China is significant, with over 250,000 actively treated patients, representing a market potential of $500 million to $700 million [19] Company Strategy and Development Direction - The company aims to accelerate global development of its ATTC programs and explore potential in-licensing and M&A opportunities [4][26] - Focus on building a strong hematology portfolio, with the first-in-class treatment for EZH2 mutation approved [11] - The company is pursuing partnerships with multinational companies to validate and add value to its ATTC platform [48] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, with multiple potential NDA filings and expected growth from new hematology products [26] - The oncology revenue guidance for 2026 is projected to be between $330 million and $450 million, reflecting strong growth expectations [7][26] - Management acknowledged the challenges faced in the U.S. market but highlighted the continued expansion of FRUZAQLA in other countries [71] Other Important Information - The company has a strong cash position of approximately $1.4 billion, allowing for accelerated development and exploration of business opportunities [4] - The ATTC platform is designed to reduce toxicities by delivering payloads directly to tumors, targeting a significant market across various cancer types [20][21] Q&A Session Summary Question: Can you elaborate on the oncology guidance for 2026? - Management indicated that the guidance reflects strong momentum and growth from new indications, with expectations for continued recovery [31] Question: What is the status of the SAFFRON readout? - The SAFFRON readout is expected to occur in mid-2026 [32] Question: Can you provide details on the ATTC platform candidates? - The first candidate, HMPL-A251, is currently enrolling HER2-expressing solid tumor patients, focusing on post-HER2 treatment settings [32] Question: How do you expect the changes in Medicare Part D to impact sales? - Management noted that the impact from Medicare changes has already been reflected in 2025 results, but they anticipate continued growth in ex-U.S. markets [71] Question: What is the strategy for partnering with the ATTC program? - The company is open to licensing out some programs to accelerate development while maintaining control over others for long-term value [48] Question: How will the move into hematology products affect sales and marketing investments? - A new business unit with dedicated sales and marketing capabilities has been established to address the hematology market [69]

Financial Data and Key Metrics Changes - Total oncology revenue for 2025 was $286 million, including $71 million from R&D-related upfront and milestone revenues [4] - Net income recorded was $457 million, primarily due to a one-time gain from the SHPL divestment of $160 million; core operations remained profitable excluding this gain [4] - R&D expenses for 2025 were $148 million, lower than 2024 as many late-stage trials were nearing completion [4] Business Line Data and Key Metrics Changes - Ex-China FRUZAQLA sales grew by 26% year-over-year, totaling $366 million in in-market sales [2] - China sales rebounded in the second half of 2025, achieving 21% growth compared to the first half [2] - ORPATHYS and Surufatinib accounted for 11% of total 2025 EMARC sales but faced competition, impacting their performance [9] Market Data and Key Metrics Changes - In the U.S., sales faced headwinds due to Medicare Part D redesign, impacting overall performance [8] - In China, ELUNATE experienced a decline of 13% in the first half but rebounded with 33% growth in the second half [8] - The ITP market potential in China is significant, with over 250,000 actively treated patients, representing a market of $500 million to $700 million [18] Company Strategy and Development Direction - The company aims to accelerate global development of its ATTC programs and explore potential in-licensing and M&A opportunities [3] - A focus on building a strong hematology portfolio is evident, with the launch of the first-in-class treatment for EZH2 mutation and follicular lymphoma [10] - The company is committed to maintaining a balance between R&D investments and commercial income generation [50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, with multiple potential NDA filings and expected growth from new hematology products [24] - The oncology revenue guidance for 2026 is projected between $330 million and $450 million, reflecting strong growth expectations [5] - Management acknowledged the challenges faced in the U.S. market but highlighted the continued expansion of FRUZAQLA in other countries [70] Other Important Information - The company has a strong cash position of approximately $1.4 billion, allowing for accelerated investments in ATTC development [3] - The ATTC platform is designed to reduce toxicities by delivering payloads directly to tumors, targeting a significant market across various cancer types [20] Q&A Session Summary Question: Can you elaborate on the oncology guidance for 2026? - Management indicated that the guidance reflects strong growth expectations, particularly from new indications and recovery momentum [28][29] Question: Why was the SAFFRON readout delayed? - The SAFFRON readout is now expected in mid-2026 [30] Question: What is the indication for the ATTC platform candidates? - The first candidate, HMPL-A251, is currently enrolling HER2 expressing solid tumor patients, focusing on post-HER2 treatment settings [30] Question: How do you expect the changes in Medicare Part D to impact sales? - Management noted that while there were impacts in 2025, they anticipate continued growth in the U.S. and other markets [70] Question: What is the strategy for the ATTC platform? - The company is considering potential licensing out of some programs while maintaining control over others to maximize long-term value [46]

Core Viewpoint - HUTCHMED has initiated the Phase III part of a clinical trial to evaluate a combination therapy for metastatic pancreatic ductal adenocarcinoma (PDAC), which is a highly aggressive cancer with poor survival rates [1][2]. Group 1: Clinical Trial Details - The trial is a multicenter, randomized, open-label, active-controlled Phase II/III study assessing the efficacy and safety of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer who have not received prior systemic therapy [2]. - A total of 62 patients were enrolled in the Phase II part, with plans to enroll approximately 400 additional patients in the Phase III part [2]. - The primary endpoint for the Phase III part is overall survival (OS), while secondary endpoints include progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), quality of life, and safety [2]. Group 2: Phase II Results - As of July 24, 2025, the median PFS for the S+C+AG regimen was 7.20 months compared to 5.52 months for the AG arm, indicating a 50.1% reduction in the risk of progression or death [3]. - The ORR was 67.7% for the S+C+AG arm versus 41.9% for the AG arm, and the DCR was 93.5% compared to 71.0% for the AG arm [3]. - Although overall survival data were immature, a favorable trend was observed with 9 events in the S+C+AG arm and 15 events in the AG arm [3]. Group 3: Drug Information - Surufatinib is a novel oral angio-immuno kinase inhibitor that targets VEGFRs, FGFR, and CSF-1R, promoting the immune response against tumor cells [4]. - Camrelizumab is a humanized monoclonal antibody targeting the PD-1 receptor, approved in China for multiple cancer indications [5]. - HUTCHMED is an innovative biopharmaceutical company focused on the development and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [6].

Core Insights - HUTCHMED will present new and updated data from several studies at the upcoming ESMO Asia Congress 2025 and ASH Annual Meeting, showcasing its commitment to advancing cancer therapies [1][2][3] Group 1: Upcoming Presentations - A first-in-human study of HMPL-A83, an anti-CD47 monoclonal antibody, will be presented, focusing on advanced solid tumors [2] - The phase II results of the FRUSICA-2 study, evaluating the combination of fruquintinib and sintilimab for renal cell carcinoma, will also be shared [2] - Surufatinib's phase II results in combination with camrelizumab and chemotherapy for metastatic pancreatic cancer will be reported [2] Group 2: Specific Study Details - HMPL-A83 presentation details include a mini oral session on December 7, 2025, led by Ye Guo [2] - Fruquintinib's results will be presented by Shanshan Wang on December 5, 2025, in a proffered paper session [2] - Surufatinib's study will be displayed as a poster by Shukui Qin [2] Group 3: Additional Studies - Several investigator-initiated studies will also be presented, including combinations of fruquintinib with other treatments for metastatic colorectal cancer [3] - The final analysis of the ESLIM-01 study on sovleplenib for chronic primary immune thrombocytopenia will be presented at the ASH Annual Meeting [3] Group 4: Product Information - Fruquintinib is a selective oral inhibitor of VEGFRs, co-developed by HUTCHMED and Eli Lilly, marketed as ELUNATE in China [4] - HMPL-A83 is a humanized anti-CD47 monoclonal antibody that disrupts cancer cells' immune evasion [5] - Savolitinib is a selective MET tyrosine kinase inhibitor developed by AstraZeneca and HUTCHMED, marketed as ORPATHYS [6] - Surufatinib is an oral angio-immuno kinase inhibitor marketed as SULANDA in China [7] - Sovleplenib is a selective small molecule inhibitor targeting Syk, with potential applications in B-cell lymphomas [8]

Core Insights - HUTCHMED will present new and updated data from several studies at the 2025 World Conference on Lung Cancer (WCLC) and the Chinese Society of Clinical Oncology (CSCO) Annual Meeting [1][2][3] Group 1: WCLC Presentations - Updated analysis from savolitinib's studies, including SACHI, SAVANNAH, and a Phase IIIb confirmatory study in non-small cell lung cancer (NSCLC) patients, will be presented [2] - Specific presentations include: - "Biomarker Concordance and Acquired Resistance in Patients with EGFRm MET-OverExp and/or Amp NSCLC" by Christina Baik on September 7, 2025 [2] - "Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy" by Yongfeng Yu on September 9, 2025 [2] - Insights from the SACHI study regarding frontline treatment duration in MET-Amplified NSCLC after third-generation EGFR-TKI failure [2] Group 2: CSCO Annual Meeting Presentations - Clinical data of HMPL-653, a novel CSF-1R inhibitor, will be presented for the first time at the CSCO Annual Meeting [3] - Specific presentations include: - A first-in-human Phase I study of HMPL-653 in patients with tenosynovial giant cell tumor by Xiaohui Niu on September 12, 2025 [3] - Updated efficacy and safety data for Fruquintinib in various cancer types, including metastatic or unresectable non-clear cell renal cell carcinoma and advanced esophageal squamous cell carcinoma [3][4] Group 3: Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery and global development of targeted therapies and immunotherapies for cancer and immunological diseases [5] - The company has successfully marketed its first three medicines in China, with the first also approved in the US, Europe, and Japan [5]

Investment Rating - The industry investment rating is Attractive [7] Core Insights - The report highlights several promising clinical trial results for various biotech companies, indicating potential best-in-class therapies in oncology and other therapeutic areas [2][3][4][5][6] - The report emphasizes the competitive landscape in the biotech sector, particularly in the context of EGFRm+ NSCLC, where DB-1310 faces significant competition [3] - The report provides a detailed analysis of multiple abstracts presented at ASCO, showcasing the efficacy and safety of various drug candidates [6][10] Summary by Relevant Sections Clinical Trial Results - DB-1311 in 3L CRPC shows a median rPFS of 8.3 months, indicating best-in-class potential [2] - DB-1310 in pre-treated EGFRm+ NSCLC demonstrates a uORR of 35.7% and mPFS of 7.0 months, competitive against peer HER3-ADCs [3] - Surufatinib + KN046 in 1L PDAC shows better response and safety, with mPFS competitive against SoC [4] - IBI363 in MSS/pMMR CRC shows consistent ORR and potential best-in-class mDoR of 7.5 months [4] Abstract Reactions - The report includes reactions to select abstracts from ASCO, indicating meaningful upside for DB-1311 and modest upside for DB-1310 [6][10] - IBI363 shows consistent results in immunotherapy-treated acral/mucosal melanoma with a DoR of 14 months [5] - ZL-1310 in r/r ES-SCLC shows an ORR of 68%, demonstrating best-in-class potential [5] Company Ratings - The report provides ratings for various companies in the healthcare sector, with notable mentions including: - 3SBio rated as ++ - Adicon Holdings rated as Overweight - Alibaba Health rated as Overweight [61]